Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Gastroenterol Clin North Am. 2000 Dec;29(4):759-73, vii.

How to treat Helicobacter pylori. First-line, second-line, and future therapies.

Author information

  • 1Laboratoire de Bactériologie, Université Victor Ségalen Bordeaux 2 and Hôpital Pellegrin, Bordeaux, France.

Abstract

Numerous trials were performed in the 1990s to define the optimal therapy for Helicobacter pylori infections. The proposed proton-pump inhibitor (PPI)-based and ranitidine bismuth citrate (RBC)-based triple therapies led to satisfactory results. Their first drawback is cost, and, for this reason, many people worldwide cannot benefit from these regimens. Failures of first-line therapies essentially are because of antimicrobial resistance, which increases with the selection pressure resulting from the use of these drugs. Second-line treatments using antimicrobial agents for which H. pylori resistance is low or nonexistent are being tested to find alternatives to the quadruple therapy. There is a need for new drugs, which should be highly effective, nonselective of resistant strains, and without side effects, to improve current regimens. These drugs may be the results of postgenomic studies.

PMID:
11190062
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk